August 25, 2021 11:28:56
- Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoids
- InMed Pharmaceutical has developed a trademarked platform called IntegraSyn that extracts five times the normally expected yields of cannabinoids from its plant sources
- IntegraSyn’s ability to increase yields may ultimately help InMed to achieve a profitable means of producing cannabinol (“CBN”) and other lesser-known cannabinoids at commercial scales
- To date, GW Pharma’s Epidiolex is the only cannabis-derived product to achieve FDA approval as a pharmaceutical, and the company’s multi-million-dollar revenues demonstrate the potential returns a pharmaceutical-level drug can achieve
British Columbia, Canada-based InMed Pharmaceuticals (NASDAQ: INM)
is developing a proprietary cannabinoid synthesis manufacturing system known as IntegraSyn with a goal of advancing its rare and lesser-known cannabinoid production to commercial levels.
“The next key milestone is to manufacture our first large-scale batch through a pharma-grade-ready process in the coming months. We will continue to optimize the process and scale up the IntegraSyn(TM)…
NOTE TO INVESTORS:
The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks
that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork